Investment
Features
FeesSafety
Academy
More
Pluang+

goeasy faces risks from LendCare issues and exec turnover; holds off dividends to focus on debt cut.

Market News
09 Jun 2026
Seeking Alpha
View Source
Bearish
pluang ai news

goeasy Ltd. is under pressure due to problems with its LendCare loan portfolio, high charge-offs, and executive turnover, leading to a cautious short-term hold rating. The company has launched a 6-point Turnaround Strategy focused on operational integration, cost savings, and emphasizing easyfinancial's direct lending to regain profitability. Dividends and share buybacks are suspended as goeasy prioritizes prudent capital allocation and aggressive debt reduction amid high leverage and past covenant breaches. Investors should watch upcoming Q2–Q4 2026 results, the July 1 audit, and the LendCare portfolio runoff before considering a buy decision.

More News

Reactive hot melt adhesives market to reach $4.29B by 2035, driven by automotive and furniture demand.

Reactive hot melt adhesives market to reach $4.29B by 2035, driven by automotive and furniture demand.

The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...

Market News
Bullish
36 minutes ago
Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...

Market News
Bullish
4 hours ago
Xenon Pharmaceuticals advances with strong Phase 3 epilepsy data, eyeing NDA filing in 2026.

Xenon Pharmaceuticals advances with strong Phase 3 epilepsy data, eyeing NDA filing in 2026.

Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...

Market News
Bullish
4 hours ago
Microsoft stock drops 30% despite strong AI-driven growth and solid earnings.

Microsoft stock drops 30% despite strong AI-driven growth and solid earnings.

Microsoft shares have fallen about 30% from their peak last year, trading near $395, despite showing strong earnings growth of around 17% and robust AI integration in its products. The market appears to undervalue Microsoft’s AI advancements, with Of...

Market News
Bullish
4 hours ago
Mips reports 72% Q2 revenue growth with strong organic gains in Europe and the U.S.

Mips reports 72% Q2 revenue growth with strong organic gains in Europe and the U.S.

Mips announced a robust 72% revenue growth for Q2 2026, driven by a 42% organic increase excluding currency and acquisition effects. Year-to-date growth stands at 53%, with strong momentum across all regions, especially Europe with 48% organic growth...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App